5-[4-(2,2-diethoxyethoxy}benzyl]thiazolidine-2,4-dione | 172648-12-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 5-[4-(2,2-diethoxyethoxy}benzyl]thiazolidine-2,4-dione
• 英文别名: 5-[4-(2,2-Diethoxyethoxy)benzyl]thiazolidine-2,4-dione；5-[[4-(2,2-diethoxyethoxy)phenyl]methyl]-1,3-thiazolidine-2,4-dione
• CAS: 172648-12-3
• 化学式: C₁₆H₂₁NO₅S
• 分子量: 339.412
• InChiKey: YIKSFCMSHIWWLA-UHFFFAOYSA-N

物化性质

• 沸点：
  511.1±45.0 °C(Predicted)
• 密度：
  1.233±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  23
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  99.2
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  5-[4-(2,2-diethoxyethoxy}benzyl]thiazolidine-2,4-dione 在 盐酸 作用下， 以 四氢呋喃 为溶剂， 生成 5-[4-(2-oxoethoxy)benzyl]thiazolidine-2,4-dione
  参考文献：
  名称：

  Heterocyclic compounds having anti-diabetic activity and their use

  摘要：

  式(I)的化合物：##STR1## [其中：X代表未取代或取代的吲哚基、吲哚啉基、氮杂吲哚基、氮杂吲哚啉基、咪唑吡啶基或咪唑吡嘧啶基；Y代表氧原子或硫原子；Z代表2,4-二氧代噻唑啉-5-基甲基、2,4-二氧代噻唑啉-5-基甲基、2,4-二氧代噁唑啉-5-基甲基、3,5-二氧代噁二唑啉-2-基甲基或N-羟基脲基甲基；R代表氢原子、烷基、烷氧基、卤原子、羟基、硝基、芳基烷基或未取代或取代的氨基；m为1至5的整数]具有降血糖和抗糖尿病活性。

  公开号：

  US05624935A1
• 作为产物：
  描述：

  4-(2,2-二乙氧基乙氧基)苯甲醛 在 palladium on activated charcoal 哌啶 、 氢气 、 苯甲酸 作用下， 以 1,4-二氧六环 、 甲苯 为溶剂， 反应 62.0h， 生成 5-[4-(2,2-diethoxyethoxy}benzyl]thiazolidine-2,4-dione
  参考文献：
  名称：

  Dual PPAR-α and -γ activators derived from novel benzoxazinone containing thiazolidinediones having antidiabetic and hypolipidemic potential

  摘要：

  2,4-Thiazolidinedione derivatives of 1,3-benzoxazinone were synthesized and evaluated for their PPAR-alpha and gamma dual activation. DRF-2519, a compound obtained through SAR of TZD derivatives of benzoxazinone, has shown potent dual PPAR activation. In ob/ob mice, it showed better efficacy than the comparator molecules. In fat fed rat model, it showed significant improvement in lipid parameters, which was better than fibrates. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.08.043

文献信息

• Thiazolidine and oxazolidine derivatives, their preparation and their
  申请人：Sankyo Company, Limited

  公开号：US05578620A1

  公开（公告）日：1996-11-26

  Compounds of formula (I): ##STR1## and salts, esters and solyates thereof and pro-drugs therefor are useful for the treatment and/or prophylaxis of a variety of disorders, including one or more of: hyperlipemia, hyperglycemia, obesity, glucose tolerance insufficiency, insulin resistance and diabetic complications.

  公式（I）的化合物：##STR1##及其盐、酯和溶剂化合物以及其前体药物对于治疗和/或预防多种疾病非常有用，包括但不限于：高脂血症、高血糖、肥胖、葡萄糖耐量不足、胰岛素抵抗和糖尿病并发症。
• Thiazolidine and oxazolidine derivatives their preparation and their
  申请人：Sankyo Company, Limited

  公开号：US05688823A1

  公开（公告）日：1997-11-18

  Compounds of formula (I): ##STR1## Z is a group of formula (iii), (iv),: ##STR2## and salts, esters and solvates thereof and pro-drugs therefor are useful for the treatment and/or prophylaxis of a variety of disorders, including one or more of: hyperlipemia, hyperglycemia, obesity, glucose tolerance insufficiency, insulin resistance and diabetic complications.

  公式(I)的化合物：##STR1## 其中，Z是公式(iii)，(iv)的基团：##STR2## 它们的盐、酯和溶剂合物以及其前药可用于治疗和/或预防多种疾病，包括但不限于：高脂血症、高血糖症、肥胖症、葡萄糖耐量不足、胰岛素抵抗和糖尿病并发症。
• Intermediate compounds in the preparation of heterocyclic compounds
  申请人：Sankyo Company, Limited

  公开号：US05739345A1

  公开（公告）日：1998-04-14

  Compounds of formula (I): ##STR1## \x9bwherein: X represents an unsubstituted or substituted indolyl, indolinyl, azaindolyl, azaindolinyl, imidazopyridyl or imidazopyrimidinyl group; Y represents an oxygen or sulfur atom; Z represents a 2,4-dioxo-thiazolidin-5-ylidenylmethyl, 2,4-dioxothiazolidin-5-ylmethyl, 2,4-dioxooxazolidin-5-ylmethyl, 3,5-dioxooxadiazolidin-2-ylmethyl or N-hydroxyureidomethyl group; R represents a hydrogen atom, an alkyl group, an alkoxy group, a halogen atom, a hydroxy group, a nitro group, an aralkyl group or a unsubstituted or substituted amino group; and m is an integer of from 1 to 5! have hypoglycemic and anti-diabetic activities. Disclosed also are intermediate compounds for the preparation of compounds of formula I.

  式(I)的化合物：##STR1## 其中：X代表未取代或取代的吲哚基、吲哚啉基、氮杂吲哚基、氮杂吲哚啉基、咪唑吡啶基或咪唑嘧啶基；Y代表氧原子或硫原子；Z代表2,4-二氧代噻唑啉-5-亚甲基、2,4-二氧代噻唑啉-5-基甲基、2,4-二氧代噁唑啉-5-基甲基、3,5-二氧代氧杂噻唑啉-2-基甲基或N-羟基脲甲基；R代表氢原子、烷基、烷氧基、卤素原子、羟基、硝基、芳基烷基或未取代或取代的氨基；m为1至5的整数！具有降血糖和抗糖尿病活性。还公开了制备式(I)化合物的中间体化合物。
• Heterocyclic compounds having antidiabetic, hypolipidemic and antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
  申请人：Reddy-Cheminor, Inc.

  公开号：US06313113B1

  公开（公告）日：2001-11-06

  The present invention relates to novel antidiabetic compounds, their tautomeric forms, their derivatives, their analogues, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel azolidinediones of the general formula (I), their analogues, their derivatives, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them

  本发明涉及新型抗糖尿病化合物、它们的互变异构体、它们的衍生物、类似物、立体异构体、多晶形态、药用可接受盐、药用可接受溶剂和含有它们的药用可接受组合物。本发明特别涉及一般式(I)的新型噁唑烷二酮、它们的类似物、衍生物、互变异构体、立体异构体、多晶形态、药用可接受盐、药用可接受溶剂和含有它们的药物组合物。
• Heterocyclic compound having anti-diabetic activity
  申请人：Sankyo Company, Limited

  公开号：US05977365A1

  公开（公告）日：1999-11-02

  Compounds of formula (I): ##STR1## [wherein: X represents an unsubstituted or substituted indolyl, indolinyl, azaindolyl, azaindolinyl, imidazopyridyl or imidazopyrinidinyl group; Y represents an oxygen or sulfur atom; Z represents a 2,4-dioxo-thiazolidin-5-ylidenylmethyl, 2,4-dioxothiazolidin-5-ylmethyl, 2,4-dioxooxazolidin-5-ylmethyl, 3,5-dioxo-oxadiazolidin-2-ylmethyl or N-hydroxyureidom ethyl group; R represents a hydrogen atom, an alkyl group, an alkoxy group, a halogen atom, a hydroxy group, a nitro group, an aralkyl group or a unsubstituted or substituted amino group; and m is an inzeger of from 1 to 5] have hypoglycemic and anti-diabetic activities.

  式(I)的化合物：##STR1## [其中：X代表未取代或取代的吲哚基、吲哚啉基、氮杂吲哚基、氮杂吲哚啉基、咪唑吡啶基或咪唑吡啶啉基；Y代表氧原子或硫原子；Z代表2,4-二氧代噻唑啉-5-亚甲基基、2,4-二氧代噻唑啉-5-基甲基、2,4-二氧代噁唑啉-5-基甲基、3,5-二氧代氧化噻唑啉-2-基甲基或N-羟基脲基乙基基团；R代表氢原子、烷基、烷氧基、卤原子、羟基、硝基、芳基烷基或未取代或取代的氨基基团；m为1至5的整数]具有降血糖和抗糖尿病活性。